化学化工学院
 首页  学院概况  学院动态  师资队伍  教育教学  学术科研  党建工作  学生工作  分析测试中心  实验示范中心  国际交流  文件下载 
教授
您的位置: 首页>师资队伍>职称分类>教授>正文

陈嘉媚
2023-02-24 16:23:54   审核人:   (点击: )

陈嘉媚简介

姓名

陈嘉媚

性别

出生年月

1979.11

学历学位

博士

 

职称

教授

系别

制药工程系

导师类型

博导、硕导

电话

18522884977

Email

chenjiamei@email.tjut.edu.cn

办公/

科研室

19号楼202

所属学科

材料科学与工程(博导)

100701 药物化学(学硕)/086000 生物与医药(专硕)/085600 材料与化工(专硕)/0703 化学(学硕)

研究

方向

1、药物晶型和共晶研究

2、纳米晶和纳米共晶研究

讲授

课程

无机化学(本科生)、药物晶型研究(研究生)、论文写作指导(研究生)

主要科研项目及代表性成果(包括鉴定项目、论文、专著、获奖、专利等):

项目:

1、国家自然科学基金面上项目:抗肿瘤药-药纳米共晶的可控合成与增溶增效研究,项目号 22271220,2023.01-2026.12,54万,第一;

2、国家自然科学基金面上项目:利用氢键超分子合成子设计与合成药物共晶以改善药物的渗透性,项目号21571194,2016.01-2019.12,76万,第一;

3、国家自然科学基金青年科学基金项目:基于晶体工程的药物共晶研究,项目号21101173,2012.01-2014.12,25万,第一;

4、中国博士后科学基金:晶体工程在药物共晶研究中的应用,项目号20110490949,2011.10-2012.09,3万,第一;

5、国家自然科学基金重点项目:双原子金属催化剂的可控合成及其协同催化作用研究,项目号 21931007,2020.01-2024.12,第二;

6、国家自然科学基金“可控自组装体系及其功能化”重大研究计划培育项目:提高药物水溶性导向的可控自组装研究,项目号91127002,2012.01-2014.12,70万,第二 

7、十一五国家“重大新药创制”科技重大专项:高生物利用度及稳定性药物晶型的制备与分析技术及产业化应用,项目号2009ZX09501-022,2009.01-2010.12,684万,第四;

8、“广东特支计划”科技创新青年拔尖人才项目,项目号2014TQ01R159,2015.04-2018.03,30万,第一;

9、河北省重点研发计划“农业高质量发展关键共性技术攻关专项”:基于药物共晶技术的兽用高效抗菌药物研究,项目号 19227505D,2019.07-2022.06,45万,第二;

10、广东省自然科学基金团队项目:药物结晶化学研究与应用,项目号S2012030006240, 2012.10-2016.10,200万,第五;

 

论文:

1、X. X. Liu, P. Shi, X. L. Dai, Y. L. Huang, T. B. Lu, J. M. Chen*, Photophysics of charge transfer cocrystals composed of fluorene and its heterocyclic analogues as donors and TCNQ as an acceptor, CrystEngComm, 2022, 24, 8449-8456,

2C. Wu, L. Gao, J. Xiong, X. L. Dai*, W. Gao, T. B. Lu, J. M. Chen*, Salts of rucaparib with dicarboxylic acids: synthesis, crystal structures and solubility aspects, CrystEngComm, 2022, 24, 7813-7820,

3B. Y. Ren, X. L. Dai, F. Zhang, X. Long, Y. L. Huang, J. M. Chen*, T. B. Lu, “Drug-Coformer-Drug” Multicomponent Crystals to Simultaneously Improve the Solubility of Two Insoluble Combined Drugs by Introduction of a Soluble Coformer, Crystal Growth & Design, 2022, 22(10), 5785-5790.

4P. Shi, X. X. Liu, X. L. Dai, J. Wang, T. B. Lu, J. M. Chen*, Near-infrared photothermal conversion properties of carbazole-based cocrystals with different degrees of charge transfer, CrystEngComm, 2022, 24, 4622-4628.

5G. L. Huang, L. Yang, B. Y. Ren, X. Y Lv, L. Y . Song, X. L. Dai*, J. M. Chen*, Simultaneously improving the physicochemical and pharmacokinetic properties of vemurafenib through cocrystallization strategy, Journal of Drug Delivery Science and Technology, 2022, 70, 103230.

6B. Y. Ren, X. L. Dai, J. Wang, T. B. Lu, J. M. Chen*, Two anhydrous forms and one monohydrate of a cocrystal of axitinib and glutaric acid: characterization, property evaluation and phase transition study, CrystEngComm, 2022, 24, 2138-2148.

7B. Y. Ren, X. L. Dai*, J. Wang, C. Wu, T. B. Lu, J. M. Chen*, Cocrystallization of axitinib with carboxylic acids: preparation, crystal structures and dissolution behavior, CrystEngComm, 2021, 23(32), 5504-5515.

8J. Wang, X. L. Dai*, T. B. Lu, J. M. Chen*, Temozolomide-Hesperetin Drug-Drug Cocrystal with Optimized Performance in Stability, Dissolution, and Tabletability, Crystal Growth & Design, 2021, 21(2), 838-846.

9J. L. Jia, X. L. Dai, H. J. Che, M. T. Li, X. M. Zhuang, T. B. Lu, J. M. Chen*, Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation, CrystEngComm, 2021, 23(3), 653-662.

10W. T. Lv, X. X Liu, X. L. Dai, X. T. Long, J. M. Chen*, A 5-fluorouracil-kaempferol drug-drug cocrystal: ternary phase diagram, characterization and property evaluation, CrystEngComm, 2020, 22(45), 8127-8135.

11Q. Q. Hao, X. L. Dai, Y. L. Huang, J. M. Chen*, T. B. Lu, Modulation of Solid-State Optical Properties of o-Hydroxynaphthoic Acids through Formation of Charge Transfer Cocrystals with TCNB, Crystal Growth & Design, 2020, 20(11), 7492-7500.

12X. L. Dai, J. Yao, C. Wu, J. H. Deng, Y. H. Mo, T. B. Lu, J. M. Chen*, Solubility and Permeability Improvement of Allopurinol by cocrystallizaiton, Crystal Growth & Design, 2020, 20(8), 5160-5168.

13Z. J. Yuan, X. L. Dai, Y. L. Huang, T. B. Lu, J. M. Chen*, Cocrystals of Penciclovir with Hydroxybenzoic Acids: Synthesis, Crystal Structures, and Physicochemical Evaluation, Crystal Growth & Design, 2020, 20(6), 4108-4119.

14X. L. Dai, W. Gao, J. H. Li, L. C. Liu, X. He, T. B. Lu, J. M. Chen*, Modulating the solubility and pharmacokinetic properties of 5-fluorouracil via cocrystallization, CrystEngComm, 2020, 22(21), 3670-3682.

15Y. Yan, X. L. Dai, J. L. Jia, X. H. Zhao, Z. W. Li, T. B. Lu, J. M. Chen*, Crystal Structures, Stability, and Solubility Evaluation of Two Polymorphs of a 2:1 Melatonin–Piperazine Cocrystal, Crystal Growth & Design, 2020, 20(2), 1079-1087.

16X. L. Dai, A. P. Voronin, Y. L. Huang, G. L. Perlovich, X. H. Zhao, T. B. Lu, J. M. Chen*, 5-Fluorouracil Cocrystals with Lipophilic Hydroxy-2-Naphthoic Acids: Crystal Structures, Theoretical Computations, and Permeation Studies, Crystal Growth & Design, 2020, 20(2), 923-933.

17Q. Tao, Q. Q. Hao, A. P. Voronin, X. L. Dai, Y. Huang, G. L. Perlovich, T. B. Lu, J. M. Chen*, Polymorphic Forms of a Molecular Salt of Phenazopyridine with 3,5-Dihydroxybenzoic Acid: Crystal Structures, Theoretical Calculations, Thermodynamic Stability, and Solubility Aspects, Crystal Growth & Design, 2019, 19(10), 5636-5647.

18X. L. Dai, A. P. Voronin, W. Gao, G. L. Perlovich, T. B. Lu, J. M. Chen*, Intermolecular interactions and permeability of 5-fluorouracil cocrystals with a series of isomeric hydroxybenzoic acids: a combined theoretical and experimental study, CrystEngComm, 2019, 21(34), 5095-5105.

19Q. Lu, J. N. Dun, J. M. Chen, S. Y. Liu *, C. C. Sun * Improving Solid-State Properties of Berberine Chloride through Forming a Salt Cocrystal with Citric Acid, International Journal of Pharmaceutics, 2019, 554, 14-20.

20Y. M. Luo, S. Q. Chen, J. L. Zhou, J. M. Chen, L. W. Tian, W. Gao, Y. Y. Zhang, A. D. Ma, L. Li *, Z. Z. Zhou * Luteolin cocrystals: Characterization, evaluation of solubility, oral bioavailability and theoretical calculation, Journal of Drug Delivery Science and Technology, 2019, 50, 248-254.

21J. M. Li, X. L. Dai, G. J. Li, T. B. Lu, J. M. Chen * Constructing Anti-Glioma Drug Combination with Optimized Properties through Cocrystallization, Crystal Growth & Design, 2018, 18(8), 4270-4274.

22X. L. Dai, J. M. Chen *, T. B. Lu * Pharmaceutical Cocrystallization: an Effective Approach to Modulate the Physicochemical Properties of Solid-State Drugs, CrystEngComm, 2018, 20(36), 5292-5316.

23Y. Huang, J. M. Li, Z. H. Lai, J. Wu, T. B. Lu, J. M. Chen * Phenazopyridine-Phthalimide Nano-Cocrystal: Release Rate and Oral Bioavailability Enhancement, European Journal of Pharmaceutical Sciences, 2017, 109, 581-586.

 

专著:

 参编《晶型药物》第二版,北京,人民卫生出版社,2019年出版

 

专利:

1、陈嘉媚,鲁统部,陈松,蔡景辉,符兆林,贺辙,王雪峰,王超志,刘永娥,陶立坚,胡高云,结晶型 1-(3-氟苯基)-5-甲基-2-(1H)吡啶酮、其制备方法及其组合物和应用,中国发明专利,专利号200980108847.9;

2、陈嘉媚,侯雪梅,鲁统部,孙朋杰,周月广,陈剑,罗兰庆,李菁,一种结晶形式的艾普拉唑钠及其制备方法,中国发明专利,专利号 201210222653.5;

3、陈嘉媚,姚加,鲁统部,卡托普利锌配合物及其制备方法和制剂,中国发明专利,专利号201410055590.8;

4、陈嘉媚,罗苏兰,钱宇,胡文浩,一种替诺福韦艾拉酚胺与香草酸的共晶及其制备方法,中国发明专利,专利号201810604704.8;

5、李金美,陈嘉媚,鲁统部,替莫唑胺和黄芩素的共晶及其制备方法,中国发明专利,专利号 201810366209.8;

6、陈嘉媚,袁玫,鲁统部,一种罗格列酮糖精盐及其制备方法,中国发明专利,专利号201810904538.3;7、陈嘉媚,元昭君,戴霞林,鲁统部,一种喷昔洛韦与3,5-二羟基苯甲酸共晶及其制备方法,中国发明专利,专利号201910850701.7;

8、陈嘉媚,吕文婷,庄晓梅,一种5-氟尿嘧啶与山奈酚的共晶及其制备方法,中国发明专利,专利号202011054450.0;

9、陈嘉媚,吕文婷,戴霞林,一种奥拉帕尼与马来酸的共晶及其制备方法,中国发明专利,专利号202010708667.2;

10、陈嘉媚,廖政,郭肖杨,吕文婷,一种奥拉帕尼与尿素的共晶及其制备方法,中国发明专利,专利号202010654160.3;

11、陈嘉媚,贾军龙,戴霞林,一种瑞戈非尼与马来酸的共晶及其制备方法,中国发明专利,专利号202010787157.9;

12、陈嘉媚,吕文婷,一种乐伐替尼与对羟基苯甲酸共晶及其制备方法,中国发明专利,专利号202010104585.7;

13、陈嘉媚,吕文婷,一种乐伐替尼与苯甲酸的共晶及其制备方法,中国发明专利,专利号202010787158.3。

 

人才称号:

1、广州市珠江科技新星,2013年

2、“广东特支计划”科技创新青年拔尖人才,2014年

3、天津理工大学“理工学者百人计划”,2018年

4、天津市特聘教授,2018

 

 

 

总访问量:

天津理工大学化学化工学院  地址:天津市西青区宾水西道391号天津理工大学19号教学楼
电话:022-60214259  邮箱:ysh@tjut.edu.cn  邮编:300384